Our Development Pipeline

Kintara Therapeutics is focused on developing unique anti-cancer compounds, supported by a strong scientific rationale for development in indications with established biomarkers, and where patients are failing, or are unable to tolerate, current therapies.

REM-001 is a Proprietary Late Stage Photodynamic Therapy (PDT) Platform

REM-001 has broad utility for the treatment of serious cutaneous oncology indications. REM-001 has been previously studied in four Phase II and/or Phase III clinical trials in patients with cutaneous metastatic breast cancer (CMBC), who had previously received chemotherapy and/or failed radiation therapy.

View Candidate

Explore Our Scientific Publications & Presentations

Dive deeper into our work by reviewing our robust catalog of scientific publications and presentations.

View Publications and Presentations